Coherus BioSciences (CHRS) Tops Q2 EPS by 14c, beats revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.22 -6.15%
EPS Growth %: +39.4%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +39.4%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.7 million versus the consensus estimate of $50.47 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- General Mills beats estimates as cost savings offset volumes
- Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
